Drug intelligence / Profile preview

GamEMab

Development stage: Phase 1
Lead developer: Gamaleya Center
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GamEMab is a monoclonal antibody developed for the emergency prevention of Ebola virus disease (EVD). It targets the glycoprotein of the Ebola virus (EBOV), acting as an inhibitor to prevent viral entry into host cells. The drug was designed for use in infectious disease settings, specifically hemorrhagic fever caused by Ebola, and has undergone Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers. The originator and active developer is the Gamaleya Research Institute of Epidemiology and Microbiology under the Health Ministry of the Russian Federation[2].

Brand names: GamEMab
Other names: GamEMab

Targets

Zaire ebolavirus glycoprotein

Beyond the preview

Go deeper on GamEMab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GamEMab.

Explore the full profile